标题
S100A9 Interaction with TLR4 Promotes Tumor Growth
作者
关键词
-
出版物
PLoS One
Volume 7, Issue 3, Pages e34207
出版商
Public Library of Science (PLoS)
发表日期
2012-03-29
DOI
10.1371/journal.pone.0034207
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Extratumoral Macrophages Promote Tumor and Vascular Growth in an Orthotopic Rat Prostate Tumor Model
- (2015) Sofia Halin et al. NEOPLASIA
- Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2014) J.-I. Youn et al. JOURNAL OF IMMUNOLOGY
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- (2011) Roberto Pili et al. JOURNAL OF CLINICAL ONCOLOGY
- High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer
- (2010) E L Wang et al. BRITISH JOURNAL OF CANCER
- Myeloid-derived suppressor cell heterogeneity and subset definition
- (2010) Elisa Peranzoni et al. CURRENT OPINION IN IMMUNOLOGY
- The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity
- (2010) Je-In Youn et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Subsets, expansion and activation of myeloid-derived suppressor cells
- (2010) Eliana Ribechini et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
- (2010) Anders Olsson et al. Molecular Cancer
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
- (2009) O Bratt et al. BRITISH JOURNAL OF CANCER
- Transforming growth factor beta (TGF-β) and inflammation in cancer
- (2009) Brian Bierie et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF
- (2009) Luigi Dolcetti et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development
- (2009) Verena Greifenberg et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate
- (2009) Kiran Yanamandra et al. PLoS One
- Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
- (2009) Per Björk et al. PLOS BIOLOGY
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
- (2008) K. Movahedi et al. BLOOD
- An Anti-Transforming Growth Factor Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments
- (2008) J.-S. Nam et al. CANCER RESEARCH
- RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis
- (2008) Olga Turovskaya et al. CARCINOGENESIS
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer
- (2008) Sui Chu Chung et al. EUROPEAN JOURNAL OF CANCER
- Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
- (2008) Ilaria Marigo et al. IMMUNOLOGICAL REVIEWS
- RAGE signaling sustains inflammation and promotes tumor development
- (2008) Christoffer Gebhardt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
- (2008) Pingyan Cheng et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells
- (2008) R Chen et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started